Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.84 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.84 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | CETP | P11597 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4223097 | 0.91 | HDAC1 (1.00) | HDAC1HDAC2HDAC3GAACETP | |
| SCHEMBL13739891 | 0.84 | HDAC1 (0.67) | HDAC1HDAC2HDAC3CETPMAPK1 | |
| SCHEMBL13735120 | 0.83 | HDAC1 (0.65) | HDAC1HDAC2HDAC3MAPK1KMT2A | |
| SCHEMBL4083428 | 0.83 | HDAC1 (0.60) | HDAC1HDAC2HDAC3GAAPKM | |
| SCHEMBL4744831 | 0.81 | SMN1; SMN2 (0.67) | HDAC1HDAC2HDAC3GAAPKM | |
| SCHEMBL29721597 | 0.79 | GAA (0.60) | HDAC1HDAC2HDAC3GAAPKM | |
| SCHEMBL17544709 | 0.79 | GAA (0.60) | HDAC1HDAC2HDAC3GAAPKM | |
| SCHEMBL28592805 | 0.79 | CYP2C19 (0.64) | HDAC1HDAC2HDAC3GAAPKM | |
| SCHEMBL21724826 | 0.79 | SIRT2 (0.63) | HDAC1HDAC2HDAC3GAAPKM | |
| SCHEMBL13972908 | 0.78 | SMN1; SMN2 (0.59) | HDAC1HDAC2HDAC3GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| CN-101563327-A | Pyrimidine kinase inhibitors | GENENTECH INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2099771-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| EP-1968950-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | DCK, DTYMK, TK1 | HDAC1 1548/4885HDAC2 1670/4885HDAC3 2193/4885 |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | DTYMK, DCK, TYMP | HDAC1 1855/4885HDAC2 1861/4885HDAC3 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.